We’re showcasing five examples of our capability in health economics and methodology at ISPOR Europe next week.
We’re looking forward to discussing our evaluations supporting the development and adoption of high impact digital and AI innovations in healthcare which cover a wide range of clinical areas including depression, diabetes, dementia, coronary artery disease and prostate cancer.
Dr James Rose, Director of Strategic and Industry Partnerships, said: “This will be our biggest presence at ISPOR Europe reflecting how we’ve grown and strengthened our knowledge and expertise over the last year. It’s a great opportunity to highlight how we’re helping our partners to navigate market access pathways and shape their value propositions towards achieving improvements in patient outcomes, NHS productivity and economic growth.”
James will be joined in Barcelona by two key members of our health economics team: Dr Mamta Bajre and Dr Ankur Singh.
The evaluation projects covered by our ISPOR posters are:
- An AI-driven tool to identify hospital patients at high short-term risk of cognitive decline and dementia – with University of Oxford
- A digital therapeutic for depression – with Otsuka Pharmaceutical Companies Europe
- Use of AI in stress echocardiography in NHS coronary artery disease prediction – with Ultromics
- An AI prediction tool for pre-diabetes and type 2 diabetes risk stratification using CT scans – with Caristo Diagnostics
- Enhancing prostate cancer management with digital health platform – with Bayer / Wave Health UK